中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
12期
1773-1774
,共2页
癌%非小细胞肺%多西他赛%奈达铂
癌%非小細胞肺%多西他賽%奈達鉑
암%비소세포폐%다서타새%내체박
Carcinoma%non-small-cell lung%Docetaxel%Nedaplatin
目的 观察多西他赛联合奈达铂在晚期非小细胞肺癌治疗中的疗效.方法 晚期非小细胞肺癌患者共72例,随机分两组.观察组采用多西他赛联合奈达铂的化疗方案,对照组采用多西他赛联合顺铂的化疗方案.观察两组化疗前后疗效、无进展时间、总生存时间以及毒副反应等.结果 观察组患者CR率8.3%、PR率38.9%、总缓解率47.2%,与对照组患者的CR率5.6%,PR率36.1%以及总缓解率(CR+PR)41.7%,差异均无统计学意义(P>0.05).两组患者无进展生存时间与总生存时间差异均无统计学意义(均P>0.05).观察组消化道反应的发生率均显著低于对照组.结论 多西他赛联合奈达铂是治疗晚期非小细胞肺癌有效的方法之一,其毒性反应小,患者易于耐受.
目的 觀察多西他賽聯閤奈達鉑在晚期非小細胞肺癌治療中的療效.方法 晚期非小細胞肺癌患者共72例,隨機分兩組.觀察組採用多西他賽聯閤奈達鉑的化療方案,對照組採用多西他賽聯閤順鉑的化療方案.觀察兩組化療前後療效、無進展時間、總生存時間以及毒副反應等.結果 觀察組患者CR率8.3%、PR率38.9%、總緩解率47.2%,與對照組患者的CR率5.6%,PR率36.1%以及總緩解率(CR+PR)41.7%,差異均無統計學意義(P>0.05).兩組患者無進展生存時間與總生存時間差異均無統計學意義(均P>0.05).觀察組消化道反應的髮生率均顯著低于對照組.結論 多西他賽聯閤奈達鉑是治療晚期非小細胞肺癌有效的方法之一,其毒性反應小,患者易于耐受.
목적 관찰다서타새연합내체박재만기비소세포폐암치료중적료효.방법 만기비소세포폐암환자공72례,수궤분량조.관찰조채용다서타새연합내체박적화료방안,대조조채용다서타새연합순박적화료방안.관찰량조화료전후료효、무진전시간、총생존시간이급독부반응등.결과 관찰조환자CR솔8.3%、PR솔38.9%、총완해솔47.2%,여대조조환자적CR솔5.6%,PR솔36.1%이급총완해솔(CR+PR)41.7%,차이균무통계학의의(P>0.05).량조환자무진전생존시간여총생존시간차이균무통계학의의(균P>0.05).관찰조소화도반응적발생솔균현저저우대조조.결론 다서타새연합내체박시치료만기비소세포폐암유효적방법지일,기독성반응소,환자역우내수.
Objective To observe the effect of docetaxel combination with nedaplatin in the treatment of patients with advanced stage of normmall-cell lung cancer.Methods 72 patients with advanced stage of nonsmall-cell lung cancer were collected and randomly divided into observation group and control group.Docetaxel combination with nedaplatin was used in observation group and docetaxel combination with cisplatin was used in control group.The curative effect,no advancement time,total live time and adverse reaction were observed in each group.Results The CR rate 8.3%,PR rate 38.9%,total remission rate 47.2% in observation group had no significant difference with control group.There was no significant difference in no advancement time and total live time between these two groups.The rate of digestive reactions was significantly lower in observation group than in control group ( all P < 0.05 ).Conclusion Docetaxel combination with nedaplatin was an effective method in the treatment of advanced stage of nonsmall-cell lung cancer.The toxic reaction was low and easily to tolerte.